LivaNova (NASDAQ:LIVN) Upgraded at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday.

LIVN has been the topic of a number of other research reports. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Mizuho dropped their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. The Goldman Sachs Group started coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. Finally, Robert W. Baird boosted their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Price Performance

NASDAQ:LIVN opened at $47.49 on Tuesday. LivaNova has a 12-month low of $43.15 and a 12-month high of $64.47. The firm has a market capitalization of $2.58 billion, a price-to-earnings ratio of 113.07 and a beta of 0.98. The stock’s 50 day moving average price is $51.70 and its two-hundred day moving average price is $51.22. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now directly owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Institutional investors and hedge funds have recently bought and sold shares of the company. Arizona State Retirement System boosted its position in shares of LivaNova by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after acquiring an additional 299 shares in the last quarter. Atria Investments Inc boosted its holdings in shares of LivaNova by 6.2% in the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after purchasing an additional 331 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after buying an additional 425 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of LivaNova by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock worth $10,039,000 after buying an additional 659 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.